Clinical Trial Update: Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of rituximab plus CAMPATH in relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAMPATH (alemtuzumab) (alemtuzumab)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: TERMINATED